These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31796213)

  • 1. Advances in systemic lupus erythematosus pathogenesis via mTOR signaling pathway.
    He J; Ma J; Ren B; Liu A
    Semin Arthritis Rheum; 2020 Apr; 50(2):314-320. PubMed ID: 31796213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?
    Fernandez D; Perl A
    Discov Med; 2010 Mar; 9(46):173-8. PubMed ID: 20350481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.
    Gu Z; Tan W; Ji J; Feng G; Meng Y; Da Z; Guo G; Xia Y; Zhu X; Shi G; Cheng C
    Aging (Albany NY); 2016 May; 8(5):1102-14. PubMed ID: 27048648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus.
    Zhao X; Wang S; Wang S; Xie J; Cui D
    Clin Immunol; 2022 Dec; 245():109153. PubMed ID: 36265758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of Treg Cell Differentiation and Function by the Interleukin-21-Mechanistic Target of Rapamycin Axis Via Suppression of Autophagy in Patients With Systemic Lupus Erythematosus.
    Kato H; Perl A
    Arthritis Rheumatol; 2018 Mar; 70(3):427-438. PubMed ID: 29161463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitor INK128 attenuates systemic lupus erythematosus by regulating inflammation-induced CD11b
    Shi G; Li D; Li X; Ren J; Xu J; Ding L; Dou H; Hou Y
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):1-13. PubMed ID: 30292636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-633 activated AKT/mTOR pathway by targeting AKT1 in lupus CD4
    Chen S; Wang Y; Qin H; Lin J; Xie L; Chen S; Liang J; Xu J
    Lupus; 2019 Apr; 28(4):510-519. PubMed ID: 30760089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal energy metabolism in the pathogenesis of systemic lupus erythematosus.
    Cao S; Jiang J; Yin H; Wang L; Lu Q
    Int Immunopharmacol; 2024 Jun; 134():112149. PubMed ID: 38692019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis.
    Caza T; Wijewardena C; Al-Rabadi L; Perl A
    Transl Res; 2022 Jul; 245():55-81. PubMed ID: 35288362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mTOR suppresses IFNα production and the STING pathway in monocytes from systemic lupus erythematosus patients.
    Murayama G; Chiba A; Kuga T; Makiyama A; Yamaji K; Tamura N; Miyake S
    Rheumatology (Oxford); 2020 Oct; 59(10):2992-3002. PubMed ID: 32160289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the mTOR and AKT genes polymorphisms on systemic lupus erythematosus risk.
    Saravani M; Shahraki-Ghadimi H; Maruei-Milan R; Mehrabani M; Mirzamohammadi S; Nematollahi MH
    Mol Biol Rep; 2020 May; 47(5):3551-3556. PubMed ID: 32319007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.
    Oaks Z; Winans T; Huang N; Banki K; Perl A
    Curr Rheumatol Rep; 2016 Dec; 18(12):73. PubMed ID: 27812954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological pathogenesis and treatment of systemic lupus erythematosus.
    Pan L; Lu MP; Wang JH; Xu M; Yang SR
    World J Pediatr; 2020 Feb; 16(1):19-30. PubMed ID: 30796732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential roles of nucleotide-binding oligomerization domain 2 in the pathogenesis of systemic lupus erythematosus.
    Li J; Wu S; Wang MR; Wang TT; Li BK; Zhu JM
    Rheumatol Int; 2014 Oct; 34(10):1339-44. PubMed ID: 24599604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the role of autophagy in systemic lupus erythematosus: A novel therapeutic target.
    Pan Q; Gao C; Chen Y; Feng Y; Liu WJ; Liu HF
    Biomed Pharmacother; 2015 Apr; 71():190-3. PubMed ID: 25960235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
    Yap DYH; Chan TM
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunometabolism and systemic lupus erythematosus].
    Xiao YB; Guo MY; Zuo XX
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 50(6):1120-1124. PubMed ID: 30562794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome.
    Lai ZW; Marchena-Mendez I; Perl A
    Clin Immunol; 2015 Jun; 158(2):148-52. PubMed ID: 25862984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The metabolic regulation in immune cells and pathogenesis of systemic lupus erythematosus ∼toward new therapeutic applications∼].
    Takeshima Y; Iwasaki Y; Okamura T; Fujio K; Yamamoto K
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):12-20. PubMed ID: 28539549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell activation via immunometabolism in systemic lupus erythematosus.
    Iwata S; Hajime Sumikawa M; Tanaka Y
    Front Immunol; 2023; 14():1155421. PubMed ID: 37256149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.